share_log

海翔药业(002099.SZ)发布2023年度业绩，净亏损4.2亿元，由盈转亏

Haixiang Pharmaceutical (002099.SZ) announced its 2023 annual results, with a net loss of 420 million yuan, changing from profit to loss

Zhitong Finance ·  Apr 28 17:30

Haixiang Pharmaceutical (002099.SZ) released its 2023 annual report. The company's revenue was 2.172 billion yuan,...

According to Zhitong Finance App, Haixiang Pharmaceutical (002099.SZ) released its 2023 annual report. The company's operating income was 2.172 billion yuan, down 19.68% from the previous year; net loss attributable to shareholders of listed companies was 420 million yuan, which changed from profit to loss; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 341 million yuan, which changed from profit to loss; basic loss per share was 0.26 yuan/share.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment